Cargando…

Angiotensin Receptor 1 Blockers Prolong Time to Recurrence after Radiofrequency Ablation in Hepatocellular Carcinoma patients: A Retrospective Study

Inhibition of angiotensin II synthesis seems to decrease hepatocellular carcinoma recurrence after radical therapies; however, data on the adjuvant role of angiotensin II receptor 1 blockers (sartans) are still lacking. Aim of the study was to evaluate whether sartans delay time to recurrence and pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Facciorusso, Antonio, Abd El Aziz, Mohamed A., Cincione, Ivan, Cea, Ugo Vittorio, Germini, Alessandro, Granieri, Stefano, Cotsoglou, Christian, Sacco, Rodolfo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599746/
https://www.ncbi.nlm.nih.gov/pubmed/33050084
http://dx.doi.org/10.3390/biomedicines8100399
_version_ 1783602955471028224
author Facciorusso, Antonio
Abd El Aziz, Mohamed A.
Cincione, Ivan
Cea, Ugo Vittorio
Germini, Alessandro
Granieri, Stefano
Cotsoglou, Christian
Sacco, Rodolfo
author_facet Facciorusso, Antonio
Abd El Aziz, Mohamed A.
Cincione, Ivan
Cea, Ugo Vittorio
Germini, Alessandro
Granieri, Stefano
Cotsoglou, Christian
Sacco, Rodolfo
author_sort Facciorusso, Antonio
collection PubMed
description Inhibition of angiotensin II synthesis seems to decrease hepatocellular carcinoma recurrence after radical therapies; however, data on the adjuvant role of angiotensin II receptor 1 blockers (sartans) are still lacking. Aim of the study was to evaluate whether sartans delay time to recurrence and prolong overall survival in hepatocellular carcinoma patients after radiofrequency ablation. Data on 215 patients were reviewed. The study population was classified into three groups: 113 (52.5%) patients who received neither angiotensin-converting enzyme inhibitors nor sartans (group 1), 59 (27.4%) patients treated with angiotensin-converting enzyme inhibitors (group 2) and 43 (20.1%) patients treated with sartans (group 3). Survival outcomes were analyzed using Kaplan–Meier analysis and compared with log-rank test. In the whole study population, 85.6% of patients were in Child-Pugh A-class and 89.6% in Barcelona Clinic Liver Cancer A stage. Median maximum tumor diameter was 30 mm (10–40 mm) and alpha-fetoprotein was 25 (1.1–2100) IU/mL. No differences in baseline characteristics among the three groups were reported. Median overall survival was 48 months (42–51) in group 1, 51 months (42–88) in group 2, and 63 months (51–84) in group 3 (p = 0.15). Child-Pugh stage and Model for End-staging Liver Disease (MELD) score resulted as significant predictors of overall survival in multivariate analysis. Median time to recurrence was 33 months (24–35) in group 1, 41 (23–72) in group 2 and 51 months (42–88) in group 3 (p = 0.001). Number of nodules and anti-angiotensin treatment were confirmed as significant predictors of time to recurrence in multivariate analysis. Sartans significantly improved time to recurrence after radiofrequency ablation in hepatocellular carcinoma patients but did not improve overall survival.
format Online
Article
Text
id pubmed-7599746
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75997462020-11-01 Angiotensin Receptor 1 Blockers Prolong Time to Recurrence after Radiofrequency Ablation in Hepatocellular Carcinoma patients: A Retrospective Study Facciorusso, Antonio Abd El Aziz, Mohamed A. Cincione, Ivan Cea, Ugo Vittorio Germini, Alessandro Granieri, Stefano Cotsoglou, Christian Sacco, Rodolfo Biomedicines Article Inhibition of angiotensin II synthesis seems to decrease hepatocellular carcinoma recurrence after radical therapies; however, data on the adjuvant role of angiotensin II receptor 1 blockers (sartans) are still lacking. Aim of the study was to evaluate whether sartans delay time to recurrence and prolong overall survival in hepatocellular carcinoma patients after radiofrequency ablation. Data on 215 patients were reviewed. The study population was classified into three groups: 113 (52.5%) patients who received neither angiotensin-converting enzyme inhibitors nor sartans (group 1), 59 (27.4%) patients treated with angiotensin-converting enzyme inhibitors (group 2) and 43 (20.1%) patients treated with sartans (group 3). Survival outcomes were analyzed using Kaplan–Meier analysis and compared with log-rank test. In the whole study population, 85.6% of patients were in Child-Pugh A-class and 89.6% in Barcelona Clinic Liver Cancer A stage. Median maximum tumor diameter was 30 mm (10–40 mm) and alpha-fetoprotein was 25 (1.1–2100) IU/mL. No differences in baseline characteristics among the three groups were reported. Median overall survival was 48 months (42–51) in group 1, 51 months (42–88) in group 2, and 63 months (51–84) in group 3 (p = 0.15). Child-Pugh stage and Model for End-staging Liver Disease (MELD) score resulted as significant predictors of overall survival in multivariate analysis. Median time to recurrence was 33 months (24–35) in group 1, 41 (23–72) in group 2 and 51 months (42–88) in group 3 (p = 0.001). Number of nodules and anti-angiotensin treatment were confirmed as significant predictors of time to recurrence in multivariate analysis. Sartans significantly improved time to recurrence after radiofrequency ablation in hepatocellular carcinoma patients but did not improve overall survival. MDPI 2020-10-08 /pmc/articles/PMC7599746/ /pubmed/33050084 http://dx.doi.org/10.3390/biomedicines8100399 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Facciorusso, Antonio
Abd El Aziz, Mohamed A.
Cincione, Ivan
Cea, Ugo Vittorio
Germini, Alessandro
Granieri, Stefano
Cotsoglou, Christian
Sacco, Rodolfo
Angiotensin Receptor 1 Blockers Prolong Time to Recurrence after Radiofrequency Ablation in Hepatocellular Carcinoma patients: A Retrospective Study
title Angiotensin Receptor 1 Blockers Prolong Time to Recurrence after Radiofrequency Ablation in Hepatocellular Carcinoma patients: A Retrospective Study
title_full Angiotensin Receptor 1 Blockers Prolong Time to Recurrence after Radiofrequency Ablation in Hepatocellular Carcinoma patients: A Retrospective Study
title_fullStr Angiotensin Receptor 1 Blockers Prolong Time to Recurrence after Radiofrequency Ablation in Hepatocellular Carcinoma patients: A Retrospective Study
title_full_unstemmed Angiotensin Receptor 1 Blockers Prolong Time to Recurrence after Radiofrequency Ablation in Hepatocellular Carcinoma patients: A Retrospective Study
title_short Angiotensin Receptor 1 Blockers Prolong Time to Recurrence after Radiofrequency Ablation in Hepatocellular Carcinoma patients: A Retrospective Study
title_sort angiotensin receptor 1 blockers prolong time to recurrence after radiofrequency ablation in hepatocellular carcinoma patients: a retrospective study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599746/
https://www.ncbi.nlm.nih.gov/pubmed/33050084
http://dx.doi.org/10.3390/biomedicines8100399
work_keys_str_mv AT facciorussoantonio angiotensinreceptor1blockersprolongtimetorecurrenceafterradiofrequencyablationinhepatocellularcarcinomapatientsaretrospectivestudy
AT abdelazizmohameda angiotensinreceptor1blockersprolongtimetorecurrenceafterradiofrequencyablationinhepatocellularcarcinomapatientsaretrospectivestudy
AT cincioneivan angiotensinreceptor1blockersprolongtimetorecurrenceafterradiofrequencyablationinhepatocellularcarcinomapatientsaretrospectivestudy
AT ceaugovittorio angiotensinreceptor1blockersprolongtimetorecurrenceafterradiofrequencyablationinhepatocellularcarcinomapatientsaretrospectivestudy
AT germinialessandro angiotensinreceptor1blockersprolongtimetorecurrenceafterradiofrequencyablationinhepatocellularcarcinomapatientsaretrospectivestudy
AT granieristefano angiotensinreceptor1blockersprolongtimetorecurrenceafterradiofrequencyablationinhepatocellularcarcinomapatientsaretrospectivestudy
AT cotsoglouchristian angiotensinreceptor1blockersprolongtimetorecurrenceafterradiofrequencyablationinhepatocellularcarcinomapatientsaretrospectivestudy
AT saccorodolfo angiotensinreceptor1blockersprolongtimetorecurrenceafterradiofrequencyablationinhepatocellularcarcinomapatientsaretrospectivestudy